Effect of High-Flow Nasal Cannula on IVC Measurements Using Point of Care Ultrasound

Sponsor
Nova Scotia Health Authority (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05264454
Collaborator
(none)
45
1
3
12
3.8

Study Details

Study Description

Brief Summary

The size of the inferior vena cava (IVC) using point of care ultrasound is used in resuscitation of patients who are critically ill and is now being used as a standard part of resuscitation in many clinical situations. Multiple factors can effect the size of the IVC including the type of oxygen devices the patient is currently on. In the ICU setting, the use of High Flow Nasal Cannula (HFNC) is often used to help in patients who are critically ill. There is some evidence to suggest that the use of HFNC can effect the size of the IVC measurement but the extent of the effect has not been well characterized. The purpose of this study is to determine the effect HFNC has on the size of the IVC measured using a point of care ultrasound.

Condition or Disease Intervention/Treatment Phase
  • Device: high flow nasal cannulae
N/A

Detailed Description

Shock is a state of decreased perfusion and inadequate oxygen delivery to tissues. This results in end organ damage and is associated with high morbidity and mortality, regardless of etiology. Shock associated with an infection is known as septic shock. In the intensive care unit (ICU) population, septic shock is the most common admission to the ICU and, with a mortality rate approaching 30%, is one of the leading causes of death. Early antibiotics and early intravenous fluid administration are a key component of resuscitation, but over-resuscitation with fluids is associated with adverse outcomes, including death. Therefore, methods to determine the ideal amount of fluid to administer are required.

Increasingly, the use of a bedside ultrasound, known as point of care ultrasound (PoCUS), can be used to determine the cause of shock and to help guide the ideal amount of fluid administration. One method for determining the appropriate amount of fluid to administer is the measurement of the size of the inferior vena cava (IVC). The IVC is a large vein that travels through the abdomen and delivers blood back to the heart. In a breathing patient, the size of the IVC varies with the breathing cycle. During inspiration the contraction of the diaphragm results in the generation of a negative pressure inside the chest cavity. This pressure change results in a decrease in size of the IVC during inspiration; contrary, during expiration, the IVC will be maximally distended. One of the best methods for determining fluid responsiveness using IVC is known as the IVC collapsibility index, which is defined as the [(Maximum diameter IVC-Minimum diameter) / Maximum diameter IVC] x 100. If the index is greater than 41% (range, 40%-42%), the LR ranged from 3.5 (95% CI, 1.1-15) to 9.3 (95% CI, 0.88-51) that the patient would respond to fluid.

One limitation to the use of PoCUS to assess the IVC is that the size of the vessel is affected by pressure inside the chest cavity. For example, patients who have obstructive sleep apnea (OSA) are often treated using a device called a continuous positive airway pressure (CPAP) machine. CPAP works by applying a constant amount of air pressure to prevent the soft tissues in the neck from collapsing and obstructing the airway. This constant pressure results in an increase of the chest cavity pressure which has been shown to increase the IVC diameter and a decreased IVC collapsibility index. This could result in an error in not administering fluid when the patient would benefit from it.

A patient population where this error may occur are those admitted to hospital with pneumonia. Pneumonia is the most common presentation of septic shock in critical care. Often times these patients present with septic shock as well as respiratory failure, which is treated with supplemental oxygen. Increasingly, high flow nasal cannulas (HFNC) have been used in the initial management of respiratory failure. Studies in the critically ill populations have demonstrated that, compared to conventional oxygen therapy, HFNC provides superior oxygenation and decreases the need for intubation. HFNC is a device that is able to generate very high flows (up to 60 L/min) at an adjustable FiO2 such that even at very high peak inspiratory flows (i.e. breathing in quickly), FiO2 remains consistent. These high flows generate a CPAP effect, with an approximately linear relationship of 1 cmH2O for every 10 L/min of flow. Therefore, it is possible that patients who are placed on HFNC may have an artificially enlarged IVC measurement by ultrasound.

Considering the increasing scope and utilization of PoCUS as well as HFNC in the treatment of respiratory failure, it is important to establish what effect HFNC has on POCUS IVC measurements. To date, only one study has examined the effect of HFNC on the size of IVC. This study was conducted in heart failure patients where the patients were all volume overloaded (distended IVC). The study placed patients in heart failure on HFNC on flows of 20 and 40L/min which resulted in a decrease in the IVC collapsibility index. However, no study has examined the effect of HFNC non-volume overloaded patients at 60L /min.

Our hypothesis is that the application of HFNC will increase in the size of the IVC and decrease the IVC collapsibility index in healthy patients.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
45 participants
Allocation:
Non-Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
intervention will be blinded to those assessing the size of the IVC
Primary Purpose:
Diagnostic
Official Title:
Effect of High-Flow Nasal Cannula on IVC Measurements Using Point of Care Ultrasound
Anticipated Study Start Date :
Jul 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: 0 L

This will be the arm where the baseline IVC assessment size is conducted at

Device: high flow nasal cannulae
The plan is to examine the effects of the size of the IVC size based upon varrying levels of high flow nasal cannulae flow
Other Names:
  • point of care ultrasound
  • Active Comparator: 30 L

    The HFNC flow will be set at 30 L / min. The IVC size will then be assessed using a POCUS

    Device: high flow nasal cannulae
    The plan is to examine the effects of the size of the IVC size based upon varrying levels of high flow nasal cannulae flow
    Other Names:
  • point of care ultrasound
  • Active Comparator: 60 L

    The HFNC flow will be set at 60 L / min. The IVC size will then be assessed using a POCUS

    Device: high flow nasal cannulae
    The plan is to examine the effects of the size of the IVC size based upon varrying levels of high flow nasal cannulae flow
    Other Names:
  • point of care ultrasound
  • Outcome Measures

    Primary Outcome Measures

    1. Inferior vena cava maximal diameter in millimeter [3 minutes after the intervention]

    Secondary Outcome Measures

    1. Inferior vena cava maximal collapsibility index [3 minutes after the intervention]

      [(Maximum diameter Inferior vena cava -Minimum diameter) / Maximum diameter Inferior vena cava] x 100

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 40 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Ambulatory

    • 18-40 years old

    Exclusion Criteria:
    • Severe lung disease (e.g. poorly controlled asthma, COPD with FEV1 <40%)

    • Congestive heart failure (diastolic dysfunction, ejection fraction < 50%, severe valvular disorders)

    • Renal failure

    • Complete nasal obstruction or facial deformities

    • BMI > 30

    • Pregnancy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 QEII Health Sciences Centre Halifax Nova Scotia Canada B3H 3G1

    Sponsors and Collaborators

    • Nova Scotia Health Authority

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Edmund Tan, Physician Lead, Nova Scotia Health Authority
    ClinicalTrials.gov Identifier:
    NCT05264454
    Other Study ID Numbers:
    • HFNCIVC1
    First Posted:
    Mar 3, 2022
    Last Update Posted:
    Mar 3, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No

    Study Results

    No Results Posted as of Mar 3, 2022